- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.01. | ILC Dover Launches Sentinel XT Horizon | ||
| 13.01. | Synthego, AstraZeneca Ink Agreement for CRISPR Gene Editing Enzyme | ||
| 13.01. | SpringWorks to Develop Rappta's First-in-Class Cancer Drug | ||
| 13.01. | Iconovo, Lonza Partner to Develop Spray-Dried Formulations | ||
| 13.01. | Canyon Labs Acquires iuvo BioScience's Lab Services and Consulting Biz | ||
| 13.01. | Telix to Acquire Pipeline, Technology Platform & Facility from ImaginAb | ||
| 13.01. | Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program | ||
| 13.01. | Johnson & Johnson Agrees to Acquire Intra-Cellular Therapies | ||
| 10.01. | Abzena Welcomes Dr. Moncef Slaoui to Its Board of Directors | ||
| 10.01. | Verdiva Bio Launches as Clinical-Stage Cardiometabolic Company | ||
| 10.01. | Nucleus Biologics Achieves EXCiPACT Certification | ||
| 10.01. | BioDuro Opens New Peptide Laboratory in Shanghai | ||
| 10.01. | Esphera SynBio Launches Project to Enhance mRNA Vaccines | ||
| 10.01. | Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody | ||
| 10.01. | Sciwind Biosciences and Verdiva Bio Enter Global Licensing Agreement | ||
| 10.01. | Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine | ||
| 10.01. | Harbour BioMed & Kelun-Biotech License TSLP Antibody to Windward Bio | ||
| 09.01. | Kindeva Drug Delivery, Emervax Partner on Vaccine Administration | ||
| 09.01. | Coronado Research Appoints EVP of Data Services and Advanced Analytics | ||
| 09.01. | Bora Biologics, DotBio Enter Strategic CMC Development Collaboration | ||
| 09.01. | 4basebio Appoints Chief Commercial Officer | ||
| 09.01. | UCB Licenses Ailux Biologics AI Platform | ||
| 09.01. | Genenta, AGC Biologics Strengthen Cell Therapy Manufacturing Pact | ||
| 09.01. | GEMMA Biotherapeutics Names May Orfali as CMO | ||
| 09.01. | Peptone Appoints Kevin Tyler Sprott as COO |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
